1月9日，国家医保局会同财政部发布通知，将职工基本医疗保险个人账户共济范围从省内拓展至全国， 支持近亲属就医购药、参保缴费。谁能用、怎么用？ ▶ 财政部、税务总局：4月1日起，取消光伏等产品增值税出口退税 财政部、税务总局日前发布公告，自2026年4月1日起，取消光伏等产品增值税出口退税。 转自：北京日报客户端 ▶ 对外卖平台市场竞争状况，国家反垄断部门开展调查评估 近日，国务院反垄断反不正当竞争委员会办公室依据《中华人民共和国反垄断法》，对外卖平台服务行 业市场竞争状况开展调查、评估。 ▶ 维护重要航运通道！中、俄、南非等国将举行海上联合演习 1月上中旬，"和平意志-2026"海上联合演习将位南非西蒙斯敦附近海空域举行，中国、俄罗斯、南非等 金砖成员国参演。 ▶ 医保个人账户跨省共济将全国推行，谁能用、怎么用？ ▶ 体育总局登山中心：严禁违规开展徒步穿越等活动 1月9日，国家体育总局登山运动管理中心发布通知，要求严禁违规开展徒步穿越等活动。 ▶ 最高法发布典型案例，明确彩礼返还裁判标准 1月9日，最高人民法院发布第三批涉彩礼纠纷典型案例，聚焦新型彩礼性质认定、恋爱期间的消费性支 出不属于彩礼等方面，其中明确 ...

（来源：千龙网） 北京市疾控局昨天（9日）介绍，本市已全面启动适龄女生国家免疫规划HPV（人乳头瘤病毒）疫苗接 种，为满13周岁女生免费接种HPV疫苗。 市疾控局介绍，2011年11月10日以后出生的满13周岁女孩可免费接种2剂次双价HPV疫苗，2剂之间的接 种间隔为6个月。如果受种者未按照常规免疫程序完成2剂次疫苗接种，应在18岁之前尽早补齐2剂次。 第2剂与第1剂接种间隔6个月，间隔期最好不要超过一年。 适龄女生可根据所在学校安排，参加校内集中接种，也可通过拨打预防接种门诊电话、现场登记、"京 通"小程序、"首都疫苗服务" App等方式预约。预防接种门诊信息可在北京市疾病预防控制局网站或北 京市疾病预防控制中心官网查询。 2025年11月10日起，我国在现行国家免疫规划疫苗基础上，将HPV疫苗纳入国家免疫规划。此前，本市 以落实2025年民生实事项目的方式，为2025年9月新入学的初一在校女生免费接种HPV疫苗。针对两项 政策如何衔接的问题，市疾控局表示，2025年9月新入学的初一在校女生，如已接种本市民生实事HPV 疫苗第1剂，可继续使用该疫苗完成全程接种。目前第1剂接种已结束。未接种过民生实事疫苗且符 ...

证券日报网讯1月5日，沃森生物（300142）在互动平台回答投资者提问时表示，目前公司共有8个自主 疫苗产品(14个品规)正式上市销售，包括：13价肺炎结合疫苗(西林瓶型和预灌封型)、双价HPV疫苗(西 林瓶型和预灌封型)、23价肺炎多糖疫苗(西林瓶型和预灌封型)、b型流感嗜血杆菌结合疫苗(西林瓶型和 预灌封型)、A群C群脑膜炎球菌多糖结合疫苗(西林瓶型和预灌封型)、ACYW135群脑膜炎球菌多糖疫苗 (西林瓶型和预灌封型)、A群C群脑膜炎球菌多糖疫苗(西林瓶型)和吸附无细胞百白破联合疫苗(西林瓶 型)。上述疫苗产品主要用于预防由特定病原微生物感染所引起的相关疾病。公司将持续狠抓产品营销 工作，制定切实可行的策略和执行措施，加强人才队伍建设，以科学普及为助力，坚定信心，强化落 实，努力加强和巩固终端渠道的覆盖率和渗透率，为公司和股东创造价值。 ...

（来源：中国妇女报） 转自：中国妇女报 新华社发 徐骏/作 10月30日，国家疾控局、国家卫生健康委、教育部、国务院妇儿工委办公室等7部门联合发布《关于将 人乳头瘤病毒疫苗纳入国家免疫规划有关工作事宜的通知》，决定自2025年11月10日起，将HPV疫苗纳 入国家免疫规划，组织各地为2011年11月10日以后出生的满13周岁女孩免费接种2剂次双价HPV疫苗。 切实降低HPV感染所致宫颈癌等疾病负担，这不仅是降低我国宫颈癌疾病家庭负担的关键一步，更是推 动全民健康的国家承诺。 ...

Group 1: Policy and Industry Dynamics - The Shanghai Stock Exchange released guidelines to expand the fifth listing standard for commercial rocket companies on the Sci-Tech Innovation Board, aiming to support the innovation and development of the commercial aerospace sector [1][17] - The guidelines consist of 14 articles detailing requirements related to business scope, "hard technology" attributes, and standards for commercial rocket enterprises, providing targeted support for high-quality companies without significant revenue [1][17] - Several rocket companies have recently submitted IPO counseling records, indicating a growing interest in capital market participation [1][17] Group 2: Market Overview and Trends - The commercial rocket industry is at a critical stage of large-scale commercialization, necessitating further support from the capital market [2][18] - The Sci-Tech Innovation Board focuses on hard technology, including sectors like electronic chips, emerging software, and new information technology services, reflecting the rise of advanced manufacturing in China [2][18] - Recent trends show a rebound in the Sci-Tech Innovation Board, particularly in sectors such as chips, information technology, and new materials [3][19] Group 3: Sector Performance - The top five industries on the Sci-Tech Innovation Board are electronics, biomedicine, power equipment, computers, and machinery, collectively accounting for 88.2% of the board's market capitalization [4][20] - The semiconductor sector has seen significant interest, with a notable rebound in chip stocks driven by demand for AI computing infrastructure [21] - The high-end equipment manufacturing sector is experiencing growth, with a 15.4% year-on-year increase in engineering machinery import and export trade, reflecting a recovery in overseas demand [22] Group 4: Investment Opportunities - The AI computing demand is expected to surge, with continued capital investment from cloud vendors driving high demand for advanced chips [21] - The domestic engineering machinery update cycle is starting, supported by favorable policies in real estate and infrastructure [22] - The pharmaceutical sector remains active, with multiple innovative drugs and medical devices receiving approvals, indicating a robust pipeline for growth [23]

薪酬审议"被遗忘"，股东监督形同虚设，这家曾市值千亿的疫苗明星企业，正在治理失序与业绩下滑的 双重压力下艰难前行。 近日，云南证监局与深交所相继向沃森生物下发《责令改正措施决定书》与《监管函》，直指公司在 2023年、2024年董事及高管薪酬未履行法定审议程序的违规行为。这一看似低级的程序疏漏，揭开了这 家生物科技公司治理结构背后的深层问题。 01 治理结构松散与监督缺位 根据《上市公司治理准则》第六十条规定，董事薪酬由股东大会决定，高管薪酬由董事会决定。然而， 沃森生物连续两年"忘记"了这一基本公司治理常识。 新质生产力会客厅联合创始发起人袁帅指出，这反映出公司内部治理结构的松散与监督机制的缺位。或 许是管理层对规则重视不足，存在侥幸心理；也可能是公司内部权力制衡失效，缺乏有效的内部监督力 量。 监管函件显示，沃森生物的行为违反了《创业板股票上市规则》及《上市公司自律监管指引》的相关规 定。 云南证监局已对公司采取责令改正的行政监管措施，并将此记录计入证券期货市场诚信档案。深交所也 明确表示，公司行为已违反上市规则多项条款。 实际上，这并非沃森生物首次在治理程序上"踩坑"。自2010年上市以来，该公司在"三 ...

本次集中采购是中国疾病预防控制中心组织的国家免疫规划疫苗集中采购项目，玉溪泽润后续还需进一 步签订采购合同并组织生产与供应。本次入围将有利于扩大公司双价HPV疫苗的销售规模，提高市场覆 盖率，促进公司相关产品的市场开拓，提升公司的品牌影响力。但此次入围企业有两家，考虑第二阶段 尚需与各省谈判份额，且接种落实周期长等因素，对公司短期内的经营业绩不会产生明显影响。 玉溪泽润双价人乳头瘤病毒疫苗（毕赤酵母）入围2025年国家免疫规划疫苗集中采购项目——双价人乳 头瘤病毒疫苗采购项目，入围单价为人民币27.5元。玉溪泽润双价HPV疫苗主要用于预防因高危型 HPV16、18型所致的相关疾病，如：宫颈癌，2级、3级宫颈上皮内瘤样病变（CIN2/3）和宫颈原位腺癌 （AIS）。该疫苗于2022年正式在国内上市，并于2024年8月通过了世界卫生组织预认证（WHOPQ认 证）。本次玉溪泽润双价HPV疫苗入围将进一步提升我国HPV疫苗的接种率，助力我国加速实现消除宫 颈癌的目标。 格隆汇12月23日丨沃森生物(300142.SZ)公布，子公司玉溪泽润生物技术有限公司（简称"玉溪泽润"）参 加了"2025年国家免疫规划疫苗集中采购 ...

Core Viewpoint - The article discusses the transformation of China's biopharmaceutical industry and highlights the role of Watson Bio in this transition, emphasizing the importance of scientific spirit and innovative practices in overcoming industry challenges [2][3]. Group 1: Scientific Spirit - The biopharmaceutical industry in China is transitioning from "catching up" to "leading," requiring a scientific spirit characterized by patriotism, innovation, pragmatism, dedication, collaboration, and education [2]. - The balance between urgent public health needs and the long-term, high-risk nature of biopharmaceutical R&D is crucial, with the scientific spirit serving as an internal stabilizer [2]. - Watson Bio invests over 20% of its annual revenue in R&D, adopts a data-driven approach, collaborates with academic institutions, and focuses on public health issues [2][3]. Group 2: Role of the Company - Watson Bio's bivalent HPV vaccine has received prequalification from the World Health Organization, marking a significant step in making vaccines accessible [3]. - The company aims to evolve from a "supplier" to a "solution partner," emphasizing technology transfer, joint R&D for regional diseases, and ecosystem building for accessibility solutions [3]. Group 3: mRNA Platform - Watson Bio has established four core technology platforms, including mRNA technology, which allows for rapid vaccine development [4]. - The mRNA platform fundamentally changes the vaccine R&D paradigm, reducing development time from years to months through modular design and rapid iteration [4]. - The strategic focus of the mRNA platform includes creating a rapid response system for emerging infectious diseases and expanding into precision medicine for cancer treatment [4].

Core Viewpoint - Watson Bio has received a marketing authorization for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Egyptian Drug Authority, marking a significant step in its international expansion efforts [1] Group 1: Company Developments - Watson Bio's vaccine products have been exported to over 24 countries and regions, with a total export volume exceeding 63 million doses [3] - The company has successfully entered new markets including Chile and Jordan for its 13-valent pneumococcal conjugate vaccine, and has also expanded its 23-valent pneumococcal polysaccharide vaccine to Chile, Mexico, and El Salvador [2] - Watson Bio has completed a localization project in Indonesia, beginning to export raw materials to local partners [2] Group 2: Industry Trends - Multiple vaccine companies are accelerating their global strategies, with significant partnerships and contracts being established, such as Beijing Kexing's $700 million deal with Brazil [2] - The overseas sales revenue of several vaccine companies has shown substantial growth, with Chengda Bio achieving a 26.96% increase and Wantai Bio seeing a 77.51% increase in overseas sales [3] - The vaccine industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition posing short-term challenges, but long-term growth prospects remain positive [3]

Core Viewpoint - The inclusion of the HPV vaccine in China's national immunization program starting from November 10, 2025, will allow eligible residents to receive the vaccine for free, significantly enhancing public health efforts against cervical cancer and related diseases [1][2][4]. Group 1: Policy and Implementation - The HPV vaccine will be provided free of charge to girls born on or after November 10, 2011, who are 13 years old, with a recommended two-dose schedule [4][6]. - The addition of the HPV vaccine increases the total number of vaccines in the national immunization program to 15, which aims to improve vaccination rates and public health [2][4]. Group 2: Market Impact - The procurement price of the bivalent HPV vaccine has decreased significantly, with a reported price of 86 yuan per dose in March 2024 and a budgeted price of 27.5 yuan per dose for 2025 [5]. - The government’s centralized procurement is expected to drive a substantial increase in HPV vaccine sales and market penetration, benefiting companies like Watson Bio, which has sufficient production capacity to meet demand [5][6]. Group 3: Health Benefits and Efficacy - Vaccination can prevent over 70% of cervical cancer cases and reduce the incidence of other HPV-related diseases, as evidenced by experiences from other countries [4][6]. - Research indicates that girls aged 9-14 produce antibody levels more than twice that of those over 15 when vaccinated, making this age group a strategic target for vaccination [6][9]. Group 4: Vaccine Options and Recommendations - There are three types of HPV vaccines available: bivalent, quadrivalent, and nonavalent, with the nonavalent vaccine providing the broadest protection against various HPV strains [7][9]. - The guidelines suggest that women who have completed the bivalent or quadrivalent vaccination do not need to receive the nonavalent vaccine unless they choose to do so based on personal circumstances [9].